We have conducted a biochemical and genetic analysis of mouse mRNA capping enzyme (Mce1), a bifunctional 597-amino acid protein with RNA triphosphatase and RNA guanylyltransferase activities. The principal conclusions are as follows: (i) the mammalian capping enzyme consists of autonomous and nonoverlapping functional domains; (ii) the guanylyltransferase domain Mce1(211-597) is catalytically active in vitro and functional in vivo in yeast in lieu of the endogenous guanylyltransferase Ceg1; (iii) the guanylyltransferase domain per se binds to the phosphorylated RNA polymerase II carboxyl-terminal domain (CTD), whereas the triphosphatase domain, Mce1(1-210) , does not bind to the CTD; and (iv) a mutation of the active site cysteine of the mouse triphosphatase elicits a strong growth-suppressive phenotype in yeast, conceivably by sequestering pre-mRNA ends in a nonproductive complex or by blocking access of the endogenous yeast triphosphatase to RNA polymerase II. These findings contribute to an emerging model of mRNA biogenesis wherein RNA processing enzymes are targeted to nascent polymerase II transcripts through contacts with the CTD. The phosphorylation-dependent interaction between guanylyltransferase and the CTD is conserved from yeast to mammals.
mRNA capping occurs by a series of three enzymatic reactions in which the 5Ј triphosphate terminus of the primary transcript is cleaved to a diphosphate by RNA triphosphatase, capped with GMP by RNA guanylyltransferase, and methylated at the N-7 position of guanine by RNA (guanine 7) methyltransferase (1) . In vivo, the capping reactions occur cotranscriptionally, i.e. the substrates for the capping enzymes are nascent RNA chains engaged within RNA polymerase II (pol II) 1 elongation complexes. There must exist a mechanism to target cap formation in vivo to transcripts made by pol II, because the capping enzymes have no inherent specificity for modifying pre-mRNAs in vitro. We and others (2) (3) (4) have suggested that targeting is achieved through direct physical interaction of one or more components of the capping apparatus with the phosphorylated carboxyl-terminal domain (CTD) of the largest subunit of pol II. This model is supported by the finding that recombinant yeast guanylyltransferase and methyltransferase proteins bind specifically and independently to the phosphorylated CTD in vitro (2) . Are such direct proteinprotein interactions conserved in higher eukaryotes? Does the triphosphatase component of the capping apparatus also interact with the CTD?
We know that the physical and functional organizations of the triphosphatase and guanylyltransferase components of the capping apparatus have diverged in fungi versus metazoans. The guanylyltransferases of Saccharomyces cerevisiae (Ceg1; 459 amino acids), Schizosaccharomyces pombe (Pce1; 402 amino acids), and Candida albicans (Cgt1; 449 amino acids) are monofunctional polypeptides that cap diphosphate-terminated RNAs (5) (6) (7) . Transfer of GMP from GTP to the 5Ј diphosphate terminus of RNA occurs in a two-stage reaction involving a covalent enzyme-GMP intermediate (8) . The GMP is linked to the enzyme through a phosphoamide (P-N) bond to the ⑀-amino group of a lysine residue within a conserved motif, KXDG, found in all known cellular and DNA virus-encoded capping enzymes (9) . The fungal guanylyltransferases display ϳ38% amino acid sequence identity overall. They are also functionally homologous, insofar as PCE1 and CGT1 can complement lethal ceg1 mutations in S. cerevisiae (6, 7) . The S. cerevisiae RNA triphosphatase is a 549-amino acid polypeptide encoded by the CET1 gene (10) . The Ceg1 and Cet1 polypeptides interact in vivo and in vitro.
Metazoan capping enzymes are bifunctional polypeptides with triphosphatase and guanylyltransferase activities (11, 12) . Yagi et al. (12) isolated triphosphatase and guanylyltransferase domain fragments of the Artemia salina capping enzyme by partial proteolysis with trypsin. However, it was not clear from this work whether the functional domains overlapped structurally. The first metazoan-capping enzyme gene was isolated recently from Caenorhabditis elegans (13, 14) . The 573amino acid nematode protein consists of a carboxyl-terminal domain homologous to yeast Ceg1 and an amino-terminal domain that has strong similarity to the superfamily of protein phosphatases that act via a covalent phosphocysteine intermediate.
We recently isolated a mouse cDNA encoding the mammalian homologue of the C. elegans capping enzyme (2) . The 597-amino acid mouse capping enzyme (Mce1) also consists of an aminoterminal phosphatase domain and a carboxyl-terminal guanylyltransferase domain. Here, we report that Mce1 is functional in vitro and in vivo. An autonomous RNA triphosphatase domain (amino acids 1-210) and an autonomous guanylyltransferase domain (amino acids 211-597) have been purified and characterized. We found that the guanylyltransferase domain per se binds to the pol II CTD and that this interaction requires CTD phosphorylation. The triphosphatase domain of mouse capping enzyme does not bind to the CTD. The phosphorylation-dependent interaction between guanylyltransferase and the CTD is conserved from yeast to mammals and provides a general mechanism for targeting caps to nascent pol II transcripts in vivo.
MATERIALS AND METHODS
Yeast Expression Plasmids-The MCE1 cDNA was cloned into a customized yeast expression vector, pYX1-His, a derivative of pYX132 (CEN TRP1) in which six consecutive histidine codons and a unique NdeI site are inserted between the NcoI and BamHI sites of pYX132 (pYX-132 was purchased from Novagen). The DNA insert of the resulting plasmid pYX1-MCE1 extended from the Mce1 translation start codon to an XhoI site located in the 3Ј UTR. pYX1-MCE1 encodes the full-length 597-amino acid Mce1 polypeptide fused in-frame with an amino-terminal 12-amino acid leader peptide (MGSHHHHHHSGH). MCE1 expression in this plasmid was under the control of a constitutive yeast TPI promoter. Amino-terminal deletion mutants of MCE1 were constructed by PCR amplification with mutagenic primers that introduced an NdeI restriction site and a methionine codon in lieu of the codons for Ser-210 or Gln-259 or an NdeI site at Met-276. The PCR products were digested with NdeI and BglII and then inserted into pYX1-MCE1 so as to replace a 1.0-kilobase pair NdeI-BglII fragment of the wild type MCE1 gene with restriction fragments encoding deleted Mce1 polypeptides. The mutated genes were named according to the amino acid coordinates of their polypeptide products, i.e. MCE1(211-597), MCE1(260 -597), and MCE1(276 -597). Alanine-substitution mutations (C126A and K294A) in MCE1 were programmed by synthetic oligonucleotides using the two-stage overlap extension method (15) . pYX1-MCE1 served as the template for the first round of amplification. The second-stage PCR products of the C126A and K294A reactions were digested with NdeI and BglII or NdeI and HindIII, respectively, and then ligated into the corresponding sites in pYX1-MCE1 in place of the wild type fragments. The presence of the desired mutations was confirmed in every case by dideoxy sequencing. We sequenced the entire restriction fragment insert in each pXY1 plasmid to exclude the introduction of unwanted mutations. A CEN TRP1 vector, pYX1-CEG1, encoding yeast Ceg1 under the control of a TPI promoter, was constructed by inserting an NcoI-HindIII fragment of plasmid pGYCE-360 (16) into pYX132.
Test of MCE1 Function by Plasmid Shuffle-Strain YBS2 (MATa ura3 trp1 lys2 leu2 ceg1::hisG pGYCE-360), which is deleted at the chromosomal CEG1 locus, is viable when it maintains an extrachromosomal copy of CEG1 on a CEN URA3 plasmid (pGYCE-360) (16) . YBS2 was transformed with pXY1-based plasmids bearing wild type and mutant alleles of MCE1. Trpϩ transformants were selected on medium lacking tryptophan. Individual colonies were patched on medium lacking tryptophan. Cells from single patches were then streaked on medium containing 0.75 mg/ml of 5-fluoroorotic acid . The plates were incubated at 30°C. Mutations scored as lethal were those that did not support colony formation after 7 days. Individual colonies of the viable MCE1 alleles were picked from the 5-FOA plate and patched to plates lacking tryptophan. All 5-FOA survivors were confirmed to be UraϪ.
Bacterial Expression Plasmids-NdeI-XhoI fragments of pYX1-MCE1, pYX1-MCE1(211-597), pYX1-MCE1(260 -597), and pYX1-MCE1(276 -597) were inserted into to the T7-based expression plasmid pET16b (Novagen). The carboxyl-terminal deletion mutant MCE1 was constructed by PCR amplification from an MCE1 template with an antisense primer that introduced a translation stop at codon 211 and a flanking XhoI restriction site. The PCR product was digested with NdeI and XhoI and inserted into pET16b.
Expression and Purification of Recombinant Mce1
Protein-A 25-ml culture of E. coli BL21(DE3)/pET-MCE1 was grown at 37°C in Luria-Bertani medium containing 0.1 mg/ml ampicillin until the A 600 reached 0.5. The culture was adjusted to 0.4 mM isopropyl-␤-D-thiogalactopyranoside, and incubation was continued at 17°C for 17 h. Cells were harvested by centrifugation, and the pellet was stored at Ϫ80°C. All subsequent procedures were performed at 4°C. Thawed bacteria were resuspended in 5 ml of Buffer A (50 mM Tris-HCl, pH 7.5, 0.2 M NaCl, 10% sucrose). Lysozyme was added to a final concentration of 50 g/ml; the suspension was incubated on ice for 10 min and then sonicated for 30 s. Triton X-100 was added to a final concentration of 0.1%, and sonication was repeated to reduce the viscosity of the lysate. Insoluble material was removed by centrifugation for 45 min at 18,000 rpm in a Sorvall SS34 rotor. The soluble extract was applied to a 0.5-ml column of Ni-NTA-agarose (Qiagen) that had been equilibrated with Buffer A containing 0.1% Triton X-100. The column was washed with the same buffer and then eluted step-wise with Buffer B (50 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 10% glycerol) containing 50, 100, 200, 500, and 1000 mM imidazole. The polypeptide compositions of the column fractions were monitored by SDS-polyacrylamide gel electrophoresis (PAGE). The recombinant Mce1 polypeptide was retained on the column and recovered in the 200 and 500 mM imidazole eluates. These two fractions were pooled and dialyzed against Buffer C (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 2 mM DTT, 10% glycerol, 0.05% Triton X-100).
Expression and Purification of Mce1 and Mce1(211-597)-500-ml cultures of E. coli BL21(DE3) harboring pET-MCE1(1-210) or pET-MCE1(211-597) were grown at 37°C until the A 600 reached 0.5. The cultures were adjusted to 0.4 mM isopropyl-␤-D-thiogalactopyranoside and incubated for 3 h at 37°C. Cells were harvested by centrifugation and stored at Ϫ80°C. Thawed bacteria were resuspended in 25 ml of Buffer A. Soluble lysates were prepared as described in the preceding section and then applied to 4-ml columns of Ni-NTA-agarose, which were eluted step-wise with 50, 100, 200, 500, and 1000 mM imidazole. The Mce1(1-210) and Mce1(211-597) polypeptides were retained on the Ni-NTA-agarose columns and recovered in the 200 and 500 mM imidazole eluates. The preparations were dialyzed against Buffer C. Enzyme fractions were stored at Ϫ80°C and thawed on ice just prior to use. Protein concentrations were determined using the Bio-Rad dye binding assay with bovine serum albumin as a standard.
Glycerol Gradient Sedimentation-Aliquots (200 l) of the dialyzed Ni-agarose preparations of Mce1, Mce1(1-210), and Mce1(211-597) were applied to a 4.8-ml 15-30% glycerol gradients containing 50 mM Tris-HCl (pH 8.0), 0.3 M NaCl, 2 mM DTT, 1 mM EDTA, and 0.1% Triton X-100. The gradients were centrifuged at 50,000 rpm for 24 h at 4°C in a Beckman SW50 rotor. Fractions (0.2 ml) were collected from the bottom of the tube. Marker proteins catalase, bovine serum albumin, soybean trypsin inhibitor, and cytochrome C were sedimented in a parallel gradient.
Enzyme-GMP Complex Formation-Standard reaction mixtures (20 l) containing 50 mM Tris-HCl (pH 8.0), 5 mM DTT, 5 mM MgCl 2 , [␣ 32 P]GTP as specified, and enzyme were incubated for 5 min at 37°C. The reactions were halted by adding SDS to a final concentration of 1%. The samples were electrophoresed through a 12% polyacrylamide gel containing 0.1% SDS. Enzyme-[ 32 P]GMP complexes were visualized by autoradiographic exposure of the dried gel and was quantitated by scanning the gel with a FUJIX BAS1000 Bio-Imaging Analyzer.
RNA Triphosphatase Assay-RNA triphosphatase activity was assayed by liberation of 32 P i from ␥-32 P-labeled triphosphate-terminated poly(A) (17) . Standard reaction mixtures (10 l) containing 50 mM Tris-HCl (pH 7.5), 5 mM DTT, 10 pmol (of triphosphate termini) of [␥-32 P]poly(A), and enzyme as specified were incubated for 15 min at 37°C. Reactions was halted by addition of 1 l of 12 N formic acid. Aliquots of the mixtures were applied to a polyethyleneimine-cellulose TLC plate that was developed with 0.75 M potassium phosphate (pH 4.3). The release of 32 P i from [␥-32 P]poly(A) was quantitated by scanning the TLC plate with a FUJIX BAS1000 Bio-Imaging Analyzer.
CTD Affinity Chromatography-Recombinant glutathione S-transferase (GST)-CTD, consisting of glutathione-S-transferase fused to the first 15 tandem heptad repeats from the mouse pol II CTD (consensus sequence YSPTSPS), was purified and coupled to glutathione agarose as described (2) . GST-CTD was phosphorylated in vitro by incubation with HeLa cell extract and ATP (2) . The phosphorylation reaction resulted in the addition of approximately 3 phosphates per molecule of GST-CTD. The GST-CTD-PO4 polypeptide was adsorbed to glutathione agarose and the resin was washed with buffer containing 1 M NaCl prior to use in affinity chromatography. The GST-CTD and GST-CTD-PO4 resins contained 3.0 mg of fusion protein per ml of agarose. Affinity chromatography was performed by mixing 25 l of GST-CTD or GST-CTD-PO4 resins with 180 -200-l samples of Mce1 proteins in binding buffer containing 20 mM HEPES (pH 7.9), 0.1 mM EDTA, 1 mM DTT, 20% glycerol, 0.1 M NaCl, 0.5 M microcystine, 1 mM ␤-glycerophosphate, 0.1% Nonidet P-40. After mixing for 1 h at 4°C, the agarose beads were collected by centrifugation, and the supernatant was removed. The resins were washed three or four times with 400 -500 l of binding buffer, and then the bound material was eluted with 100 l of binding buffer containing 0.9 M NaCl. Aliquots of the input sample and the 0.9 M NaCl eluates were analyzed by SDS-PAGE.
RESULTS
Mammalian Capping Enzyme-We have isolated a mouse cDNA that encodes Mce1, a putative mRNA capping enzyme (GenBank TM accession no. AF034568). The size of the Mce1 polypeptide (597-amino acids; 68 kDa) agrees with the size of the 68-kDa enzyme-GMP complex formed by the capping enzyme isolated from mouse cell extracts (18) . The amino acid sequence of Mce1 suggests that it is a bifunctional enzyme consisting of an amino-terminal phosphatase domain and a C-terminal guanylyltransferase domain. In this respect, it resembles the C. elegans capping enzyme (13, 14) , to which it displays 43% sequence identity. The carboxyl-terminal portion of Mce1 contains the defining sequence motifs of the covalent nucleotidyl transferase superfamily (9), including the KX-DGXR sequence that constitutes the active site. The lysine side chain within this motif (Lys-294 in Mce1) reacts with GTP to form a covalent enzyme-GMP intermediate. The amino-terminal portion of Mce1 contains the (I/V)HCXAGXGR(S/T)G signature motif of the dual-specificity protein phosphatase/protein tyrosine phosphatase enzyme family. These proteins catalyze phosphoryl transfer from a protein phosphomonoester substrate to the thiol of a cysteine on the enzyme to form a covalent phosphocysteine intermediate, which is then attacked by water to liberate phosphate (19) . The cysteine within the signature motif is the active site of phosphoryl transfer and is thus essential for reaction chemistry. Cys-126 is predicted to be the active site of phosphoryl transfer by Mce1.
Catalytic Activity of Mouse Capping Enzyme-The biochemical properties of the mammalian capping enzyme were examined after expressing Mce1 and its component domains in bacteria. First, the full-length MCE1 coding sequence was inserted into an inducible T7 RNA polymerase-based pET vector such that a histidine-rich amino-terminal leader (His-tag) was fused to the 597-amino acid Mce1 polypeptide. The pET-Mce1 plasmid was introduced into E. coli BL21(DE3), a strain that contains the T7 RNA polymerase gene under the control of a lacUV5 promoter. A 68-kDa polypeptide corresponding to Histagged Mce1 was detected by SDS-PAGE in whole-cell and soluble lysates of isopropyl-␤-D-thiogalactopyranoside-induced bacteria ( Fig. 1A and data not shown). To assay guanylyltransferase activity of the expressed Mce1 protein, we incubated soluble protein from induced bacteria in the presence of [␣-32 P]GTP and a divalent cation. This resulted in the formation of a 32 P-labeled nucleotidyl-protein adduct that migrated as a 68-kDa species during SDS-PAGE ( Fig. 1A ). Three other polypeptides in the range of 45-55 kDa were labeled with GMP to a lesser extent. We detected no label transfer from GTP to polypeptides of these sizes in extracts prepared from bacteria that lacked the MCE1 gene (not shown). Purification of the His-tagged 68-kDa Mce1 guanylyltransferase was achieved by adsorption to Ni-agarose and elution with 200 -500 mM imidazole (Fig. 1A) . The imidazole eluate fractions were highly enriched with respect to Mce1, as judged by SDS-PAGE ( Fig.  1A, left panel) . Note that the lower molecular weight polypeptides with guanylyltransferase activity were recovered in the Ni-agarose flow-through and wash fractions ( Fig. 1A, right  panel) , which suggested that these were proteolytic fragments of Mce1 that lacked the amino-terminal His-tag.
The Ni-agarose Mce1 preparation was centrifuged through a 15-30% glycerol gradient. The fractions were assayed for enzyme-GMP complex formation and for RNA triphosphatase. The latter activity was detected by the release of 32 P i from ␥ 32 P-labeled poly(A). A single peak of guanylyltransferase activity was coincident with the RNA triphosphatase activity profile ( Fig. 2A ). Mce1 sedimented at 3.9 S relative to marker proteins centrifuged in a parallel gradient. We surmise from this experiment that recombinant Mce1 is a bifunctional monomeric enzyme. Autonomous Guanylyltransferase and Triphosphatase Domains-To evaluate whether the carboxyl-terminal portion of Mce1 constituted an autonomous functional guanylyltransferase domain, we expressed the protein segment from residues 211-597 as a His-tagged fusion protein. The choice of residue 211 as a domain breakpoint was based on its location 84 amino acids from the putative Mce1 active site Lys-294; the active site lysine of the monofunctional Chlorella virus guanylyltransferase is located 82 amino acids from its amino terminus (20, 21) . We found that isopropyl-␤-D-thiogalactopyranoside-induced bacteria accumulated substantial amounts of a soluble 46-kDa polypeptide corresponding to Mce1(211-597), which reacted with [␣-32 P]GTP to form a 47-kDa radiolabeled enzyme-GMP adduct (Fig. 1B) . Mce1(211-597) adsorbed to Niagarose and was eluted at 200 -500 mM imidazole (Fig. 1B) . Mce1(211-597) sedimented as a discrete 2.8 S peak during glycerol gradient centrifugation (Fig. 2B ). We surmise that Mce1 the guanylyltransferase component is a monomer in solution.
Induced expression of the amino-terminal portion of Mce1 from residues 1-210 as a His-tagged fusion protein resulted in the accumulation of a soluble 28-kDa polypeptide that could be adsorbed to Ni-agarose and eluted with 200 -500 mM imidazole (Fig. 3A) . Mce1(1-210) was recovered in nearly homogeneous form at this stage. The Ni-agarose preparation was highly active as an RNA triphosphatase (see below). As one might expect, Mce1(1-210) was incapable of forming a covalent adduct with [␣-32 P]GTP (not shown). Mce1(1-210) sedimented in a glycerol gradient as a discrete peak of 2.5 S (Fig. 3B) . The RNA triphosphatase activity profile coincided with the abundance of the 28-kDa Mce1(1-210) polypeptide. We conclude from these experiments that the mammalian capping enzyme is composed of autonomous nonoverlapping triphosphatase and guanylyltransferase domains.
Characterization of the RNA Triphosphatase Domain-The standard RNA triphosphatase reaction contained 50 mM Tris-HCl (pH 7.5) and 1 M ␥ 32 P-labeled poly(A). The extent of ␥-phosphate hydrolysis during a 15-min incubation at 37°C was proportional to input Mce1(1-210) (Fig. 4A ). In the linear range of enzyme dependence, 1 pmol of 32 P i was released per fmol of protein. The specific activity of the Ni-agarose preparation was 37 units/g. (One unit of enzyme releases 1 nmol of 32 P i from ␥ 32 P poly(A) in 15 min.) A kinetic analysis showed that the initial rate of P i release was proportional to enzyme concentration (Fig. 4B ). Mce1(1-210) hydrolyzed 1.2-2 molecules of P i /enzyme/s at steady state. RNA triphosphatase activity was optimal in 50 mM Tris buffer at pH 7.0 -7.5; the extents of ␥-phosphate release at pH 6.0 and pH 9.5 were 70 and 35%, respectively, of the activity seen at pH 7.5 (not shown). Activity was optimal in the absence of a divalent cation and was unaffected by EDTA. Inclusion of divalent cations elicited a concentration-dependent inhibition of RNA triphosphatase activity (Fig. 4C) . 75% inhibition was observed at 0.5 mM MgCl 2 or MnCl 2 . Mce1(1-210) did not catalyze release of 32 P i from [␥-32 P]ATP (not shown).
Characterization of the Guanylyltransferase Domain-Formation of the covalent enzyme-GMP complex by Mce1(211-597) was dependent on the concentration of GTP from 0.01 to 2 M (Fig. 5A ). The yield of guanylated enzyme plateaued at 5-10 M GTP; we estimated that at least 30% of the enzyme molecules were labeled with GMP in vitro. (It has been our experience that a significant fraction of any recombinant guanylyltransferase purified from bacteria is already guanylylated and thus cannot be labeled during the in vitro reaction.) Enzyme-GMP complex formation was strictly dependent on a divalent cation cofactor. Either magnesium or manganese sufficed; ac- tivity was optimal at 1-2 mM MnCl 2 or 5-10 mM MgCl 2 (Fig.  5B ). The rate of enzyme-guanylate formation was slightly greater in the presence of manganese versus magnesium (Fig.  5C ). The Ni-agarose preparation of Mce1(211-597) displayed trace levels of RNA triphosphatase activity. The specific activity (0.02 units/g of protein) was 0.05% that of Mce1(1-210). The residual triphosphatase was resolved from the guanylyltransferase activity during glycerol gradient sedimentation of Mce1(211-597), suggesting that this phosphatase was an E. coli contaminant. We surmise that the guanylyltransferase domain of Mce1 has no triphosphatase activity per se.
To confirm that the Mce1 domains actually catalyzed cap formation on triphosphate RNA ends, we incubated Mce1(1-210) and Mce1(211-597) together with unlabeled triphosphateterminated poly(A) in the presence of [␣-32 P]GTP and 0.1 mM MnCl 2 . The RNA was recovered free of GTP by several rounds of TCA precipitation, and then deproteinized and ethanol precipitated. Digestion of the labeled RNA with nuclease P1 liberated a single labeled species that migrated during PEI cellulose thin layer chromatography with GpppA (not shown).
Mce1 Activity in Vivo-To test whether the mouse capping enzyme was functional in vivo, we examined the ability of the wild type full-length MCE1 cDNA to complement a ceg1 null mutation by using the plasmid shuffle technique (6, 16) . MCE1 was cloned into a yeast CEN TRP1 expression plasmid under the control of a constitutive yeast TPI promoter. The MCE1 plasmid was introduced into YBS2, a yeast strain in which the chromosomal CEG1 locus is deleted and that is dependent for growth on maintenance of an extrachromosomal copy of CEG1 on a CEN URA3 plasmid. Trpϩ transformants were plated on medium containing 5-FOA to select against retention of the wild type CEG1 gene. Cells bearing the TRP1 MCE1 plasmid grew readily on 5-FOA, whereas cells containing the TRP1 vector plasmid were incapable of growth on 5-FOA. A mutated allele, MCE1-K294A, in which the active site nucleophile of the guanylyltransferase Lys-294 was substituted by alanine, was completely incapable of supporting yeast growth in the plasmid shuffle assay (Fig. 6A ). We conclude that the mammalian capping enzyme is functional as a guanylyltransferase in vivo. Cells transformed with MCE1(211-597) were also able to form colonies on 5-FOA, signifying that the guanylyltransferase domain by itself could replace Ceg1 in vivo. We noted that FOA-resistant MCE1(211-597) colonies arose with a slight delay compared with MCE1 transformants. The FOA-selected MCE1 and MCE1(211-597) isolates were tested for growth on rich medium in parallel with a strain bearing CEG1 in the TPI-based vector. MCE1 cells grew as well as CEG1 cells; however, MCE1(211-597) cells grew somewhat more slowly at 30°C, as gauged by colony size (Fig. 6B ). Growth of MCE1 and MCE1(211-597) cells was unaffected at 37°C (not shown).
To define the amino-terminal boundary of the guanylyltransferase domain, we constructed truncated alleles MCE1(260 -597) and MCE1(276 -597). Neither allele was capable of sustaining growth of the ceg1 strain on 5-FOA (Fig. 6A ). Expression of Mce1(260 -597) in bacteria resulted in the production of predominantly insoluble protein; what little soluble recombinant protein was obtained was inactive in enzyme-GMP complex formation (not shown). We infer that aminoterminal truncation to 35 amino acids upstream of the active site Lys-294 abrogates mouse guanylyltransferase activity. This is in accord with the observations that an amino-terminal deletion of the yeast guanylyltransferase to 32 amino acids upstream of its active site was lethal in vivo and that the recombinant truncated yeast protein was catalytically inactive in vitro (16) .
Interaction of Mce1 with the Pol II CTD-We used affinity chromatography to analyze the binding of mouse capping enzyme and its constituent domains to the pol II CTD. The test samples were incubated in parallel with a glutathione-Sepharose resin containing an immobilized ligand composed of either (i) glutathione S-transferase fused to the first 15 tandem heptad repeats of the mouse pol II CTD (consensus sequence YSPTSPS) or (ii) GST-CTD fusion protein that had been phosphorylated in vitro using HeLa nuclear extract as a source of kinase activity. The phosphorylation reaction resulted in the addition of approximately 3 phosphates per molecule of GST-CTD. After phosphorylation in vitro, the GST-CTD resin was washed extensively with 1 M NaCl to remove residual non-CTD proteins before performing affinity chromatography with mouse capping enzyme. The 68-kDa full-length Mce1 protein (residues 1-597) was prepared by in vitro translation in the presence of [ 35 S]methionine, and the translation product was subjected to affinity chromatography. We found that 35 S-labeled Mce1 bound specifically to the phosphorylated CTD (Fig.  7A, lane P) but not to the nonphosphorylated CTD control (lane C). The 46-kDa Mce1(211-597) guanylyltransferase domain by itself also bound specifically to phosphorylated CTD (Fig. 7A) . In contrast, the RNA triphosphatase domain Mce1(1-210) did not interact with either phosphorylated or nonphosphorylated CTD (Fig. 7A ). We conclude that the triphosphatase domain has no intrinsic affinity for the CTD and that its recruitment to the pol II transcription complex is mediated via its connection in cis to the guanylyltransferase. Guanylyltransferase deletion mutants Mce1(260 -597) and Mce1(276 -597) were unable to bind the phosphorylated CTD (Fig. 7A) . Apparently, deletion of the segment of Mce1 from residues 211-259 disrupts CTD-PO4 recognition as well as guanylyltransferase activity.
CTD recognition by the isolated guanylyltransferase domain was confirmed by performing affinity chromatography with recombinant proteins produced in E. coli. The 46-kDa Mce1(211-597) polypeptide bound the CTD-PO4 resin and was recovered in the high salt eluate. It did not bind to the control CTD resin (Fig. 7B, upper panel) . Assay of the fractions for enzyme-GMP complex formation confirmed that the guanylyltransferase bound specifically to the phosphorylated CTD (Fig.  7B, lower panel) . The recombinant triphosphatase domain Mce1(1-210) was not capable of binding to either CTD or CTD-PO4 (Fig. 7B) .
Cis Negative Effect of an Active Site Mutation of the RNA Triphosphatase on Mce1 Function Yeast-Yeast cells bearing MCE1-C126A, an allele with an alanine substitution at the active site cysteine of the triphosphatase domain, formed very tiny colonies on 5-FOA plates, even after 6 days of incubation.
This contrasted starkly with the behavior of MCE1 cells, which formed colonies of normal size after 2 days on 5-FOA. MCE1-C126A cells displayed a severe growth defect when plated on rich medium at 30°C (Fig. 6B) and were unable to grow on YPD plates at 37°C (not shown). The growth suppressive effects of an inactivating point mutation in the triphosphatase were far more severe than a complete deletion of the triphosphatase domain (Fig. 6B ). We hypothesize that the C126A mutation interferes with the endogenous yeast triphosphatase, either by sequestering the nascent pre-RNA ends in a nonproductive complex or by blocking access of the yeast triphosphatase to RNA polymerase II. terminal domain (13) , but the guanylyltransferase activity could not be demonstrated. We found that the proximal margin of the active guanylyltransferase domain is located 84 amino acids upstream of the presumptive active site nucleophile Lys-294. This is in keeping with the positions of the N termini of the yeast and Chlorella virus guanylyltransferases 67-82 residues upstream of their respective lysine nucleophiles (6, 7, 16, 20, 22) . The fact that the in vivo activity of Mce1 is abrogated by the K294A mutation supports our designation of this residue as the active site. Substitutions of the equivalent residues of Ceg1 and Pce1 are also lethal in vivo (6, 16, 22) . The function of the Mce1 guanylyltransferase domain is abolished when residues 211-259 are deleted. Deletion to a similar point of the yeast guanylyltransferase Ceg1 is also lethal (16) . In the crystal structure of Chlorella virus guanylyltransferase, the analogous amino-terminal segment is located on the protein surface and consists of two antiparallel ␤-sheets followed by an ␣-helix (21) . This region contains no residues that make direct contact with GTP in the enzyme-GTP cocrystal (21) . The fact that recombinant Mce1(260 -597) expressed in bacteria was predominantly insoluble complicated efforts to distinguish whether the loss of activity upon amino-terminal truncation was caused by defective protein folding or a primary defect in catalysis.
DISCUSSION

Functional Domains of Mammalian Capping Enzyme-
The RNA triphosphatase domain of Mce1 is contained within a segment consisting of residues 1-210. Using triphosphateterminated poly(A) as a substrate, we determined a steadystate turnover number of 1-2 molecules of P i release per second per enzyme. This value is quite close to the turnover number of 0.5-0.8 s Ϫ1 reported for the RNA triphosphatase component of the vaccinia capping enzyme (23) , which acts via a different mechanism (see below). The Mce1 RNA triphosphatase activity is lower in the presence of divalent cations, which are essential for the guanylyltransferase reaction. However, because ␥-phosphate cleavage is much faster than RNA guanylylation, an order of magnitude rate decrement in the triphosphatase step is unlikely to limit the overall rate of cap formation (1) . The finding that yeast ceg1 cells expressing the full-length Mce1 protein grow slightly better than cells containing the mouse guanylyltransferase domain alone suggests that an active triphosphatase in cis enhances Mce1 function in yeast. A triphosphatase active site mutation C126A exerts a strong negative effect on yeast cell growth. The CET1 gene encoding yeast RNA triphosphatase is essential (10) . Assuming that the RNA triphosphatase activity of Cet1 is critical for cell growth, FIG. 6. Complementation of ⌬ceg1 by MCE1. A, the polypeptide encoded by wild type and mutant alleles of MCE1 are depicted as horizontal bars with N termini at the left and C termini at the right. The positions of the active site cysteine (Cys-126; C) for RNA triphosphatase and the active site lysine (Lys-294; K) for the guanylyltransferase are indicated. Gene function was tested by plasmid shuffle. Complementation by plasmids containing MCE1 alleles was gauged relative to a CEG1 control plasmid. Alleles that supports the formation of wild type sized colonies after 3 days on 5-FOA are scored as ϩϩϩ. Alleles that yielded slightly smaller colonies are scored as ϩϩ, whereas those that required 7 days to form macroscopic colonies are denoted by ϩ. Lethal mutations (Ϫ) were those that formed no colonies after 7 days. WT, wild type. B, YBS2 derivatives bearing the indicated capping enzyme genes under the control of a TPI promoter were streaked on YPD agar plates. The plates were photographed after incubation for 4 days at 30°C. then we interpret our results as indicating that (i) the mouse guanylyltransferase domain alone can cooperate with, or at least not interfere with, the function of the yeast triphosphatase, and (ii) the presence of a catalytically inert mouse triphosphatase linked to the catalytically active guanylyltransferase somehow blocks the action of the endogenous yeast enzyme.
Our findings concerning the domain structure of Mce1 agree with earlier reports that the guanylyltransferases isolated from rat liver and brine shrimp copurify with an RNA triphosphatase activity (11, 12) . In the case of the brine shrimp protein, Yagi et al. (12) showed that both catalytic activities residue within a single 73-kDa polypeptide that was converted by partial proteolysis into catalytically active domains: a 20-kDa triphosphatase module could be separated from a 44-kDa fragment guanylyltransferase domain. The sizes of these two active fragments are consistent with those of the two autonomous domains of the mouse capping enzyme identified in the present study. It is therefore likely that bifunctional triphosphataseguanylyltransferase enzymes are present in all higher eukaryotes.
Evolution of the Capping Apparatus-The linear order of amino-terminal RNA triphosphatase and carboxyl-terminal guanylyltransferase domains in Mce1 is superficially similar to the arrangement of the triphosphatase and guanylyltransferase active sites in the vaccinia capping enzyme (24 -27) . However, the amino acid sequences of the Mce1 and vaccinia amino-terminal segments are unrelated, and the properties of the vaccinia triphosphatase differ from those of the metazoan triphosphatases in two key respects: (i) lack of domain autonomy, and (ii) divalent cation dependence. The vaccinia triphosphatase and guanylyltransferase active sites are distinct, but the two activities are not partitioned into discrete and separable structural modules as they are in Mce1. Instead, moieties on the vaccinia enzyme that are essential for triphosphatase and guanylyltransferase activity overlap within a 545-amino acid polypeptide (23, 26, 27) . The triphosphatase activity of the vaccinia capping enzyme depends absolutely on a divalent cation cofactor, whereas the rat liver and brine shrimp triphosphatases, as well as the recombinant C. elegans and mouse triphosphatases, require no divalent cation for activity (in fact, they are inhibited by divalent cations). The sequences of the C. elegans and mouse enzymes indicate that ␥-phosphate cleavage occurs through a phosphoenzyme intermediate. Mutation of the active site cysteine of the C. elegans triphosphatase domain abolished enzyme activity (13) . We have been unable to detect a phosphoenzyme intermediate for the vaccinia triphosphatase, which suggests that covalent catalysis does not apply. Mutational analysis of the vaccinia triphosphatase provides additional evidence for a distinct mechanism. We have identified four acidic side chains that are essential for catalysis by vaccinia triphosphatase and are conserved among the poxvirus and African swine fever virus capping enzymes (26, 27) . One or more of these acidic residues is likely to bind the essential metal ion(s). The RNA triphosphatase isolated from S. cerevisiae, also depends completely on a divalent cation cofactor (28) . The amino acid sequence of yeast Cet1 bears no similarity to the mammalian triphosphatase domains, but it does display local similarities to the vaccinia triphosphatase. We surmise that higher eukaryotes have diverged from vaccinia and yeast with respect to both mechanism and structure of the triphosphatase component of the capping machinery. In contrast, the reaction mechanism and structure of the guanylyltransferase components are conserved in yeasts, metazoans, and DNA viruses (14, 21) .
Interaction of the Capping Apparatus with the CTD of RNA to bind the pol II transcription complex, be it through the CTD or some other constituent of the complex. In either case, it appears that poisoning the mouse triphosphatase active site in the full-length Mce1 enzyme antagonizes the yeast capping system in vivo in a way that deletion of the triphosphatase domain does not. Recruitment of guanylyltransferase to the phosphorylated CTD neatly accounts for pol II specificity of capping and also provides a means of traffic control whereby CTD-interacting factors bind and dissociate from polymerase at the appropriate times in the transcription cycle without getting in each other's way. During preinitiation complex formation, the unphosphorylated CTD interacts with several general transcription factors and the SRB/mediator component of the pol II holoenzyme (37) . Phosphorylation of the CTD presumably destabilizes these contacts and makes the CTD available for a novel set of interactions with the capping enzymes. Our findings contribute to an emerging picture of the CTD as a landing pad for macromolecular assemblies that regulate mRNA synthesis and processing (38, 39) . Other recent studies indicate that protein components of the pre-mRNA splicing and 3Ј cleavagepolyadenylation assemblies also bind to the CTD (40, 41) . The role of CTD phosphorylation in those interactions remains to be clarified. Thus far, only the capping enzymes display a strict requirement for CTD phosphorylation.
